Mifepristone-misoprostol abortion: a trial in rural and urban Maharashtra, India.
As several important policy questions remain regarding the use of medical abortion in developing countries, we investigated the safety, efficacy, and acceptability of mifepristone-misoprostol abortion in the outpatient family planning departments of two urban hospitals and one rural hospital in India. Nine-hundred women (with gestations of < or =63 days in the urban sites and < or =56 days in the rural site) received 600 mg mifepristone followed 48 h later by 400 microg oral misoprostol in the clinic. Four point four percent or fewer urban women and 1.0% rural women were lost to follow-up. Perfect and typical-use failure rates were low at all sites. While rural women reported fewer side effects at all sites, the vast majority of women were satisfied with their medical abortions. Medical abortion can be offered safely, effectively, and acceptably in the outpatient family planning departments of urban and rural hospitals in India.
Coyaji
Kurus
K
K.E.M. Hospital, Pune, India.
Elul
Batya
B
Krishna
Usha
U
Otiv
Suhas
S
Ambardekar
Shubha
S
Bopardikar
Arti
A
Raote
Veena
V
Ellertson
Charlotte
C
Winikoff
Beverly
B
D000019:Abortifacient Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000028:Abortion, Induced; D000284:Administration, Oral; D000328:Adult; D005193:Family Planning Services; D005260:Female; D006801:Humans; D007194:India; D015735:Mifepristone / Q000008:administration & dosage / Q000627:therapeutic use*; D016595:Misoprostol / Q000008:administration & dosage / Q000627:therapeutic use*; D017060:Patient Satisfaction; D011247:Pregnancy; D011446:Prospective Studies; D012423:Rural Health; D014504:Urban Health
D000019:Abortifacient Agents; D016595:Misoprostol; D015735:Mifepristone